Included in the formulation
АТХ:C.05.C.A Bioflavonoids
C.05.C.A.01 Rutozid
Pharmacodynamics:Derivative routine; effects on capillaries and veins, a decrease in the rate of water filtration in capillaries and permeability of microvasculature vessels for proteins, a reduction in the spacing between endothelial cells, inhibition of aggregation, and an increase in the degree of deformability of erythrocytes.
Pharmacokinetics:After the application of the gel, the active substances penetrate through the skin and are detected in it after 30 minutes, in the subcutaneous fat - after 2-5 hours. The maximum concentration in the plasma is detected after oral administration after 1-9 h. Elimination is carried out mainly with feces and, to a lesser extent, kidneys. Half-life with oral administration 10-25 h.
Indications:Varicose veins with pain and edematous syndromes, superficial thrombophlebitis, trophic disorders and ulcers in chronic venous insufficiency, postthrombotic syndrome, post-varicose veins removal, hemorrhagic diathesis, capillarotoxicosis, diabetic retinopathy and angiopathy, trophic disorders after radiation therapy; pain and swelling after trauma (for external use).
VII.H30-H36.H36.0 * Diabetic retinopathy (E10-E14 + with common fourth sign .3)
IX.I70-I79.I79.2 * Peripheral angiopathy in diseases classified elsewhere
IX.I80-I89.I80 Phlebitis and thrombophlebitis
IX.I80-I89.I83 Varicose veins
IX.I80-I89.I83.0 Varicose veins of the lower extremities with ulcer
IX.I80-I89.I87.0 Postphlebitic syndrome
IX.I80-I89.I87.2 Venous insufficiency (chronic) (peripheral)
XIX.T08-T14.T14.0 Superficial injury of unspecified area of the body
Contraindications:I trimester of pregnancy, hypersensitivity to rutozides.
Carefully:Hypersensitivity.
Pregnancy and lactation:Adequate and well-controlled studies in humans and animals have not been conducted. Application in the I trimester is contraindicated. There is no information on the penetration into breast milk. Do not apply!
Category of recommendations for FDA is not defined.
Dosing and Administration:When taken orally in tablets, the initial dose of 300 mg 3-4 times a day or 500 mg 2 times a day.The effect develops within 2 weeks. Treatment continues at the same dose or reduces it to a minimal maintenance dose (600 mg per day). After cessation of treatment, the effect is maintained for 4 weeks.
In a gel dosage form - apply externally.
Side effects:Ingestion: possible - dyspeptic symptoms, headache, hot flashes; rarely - skin rash.
With external application: allergic reactions (skin rash), local irritant effect.
Interaction:Ascorbic acid together with rutozide enhances effects.
Special instructions:Insufficient evidence of the efficacy of phlebotonic agents in chronic venous insufficiency. There are suggestions of efficacy in puffiness, but the clinical significance of the effect is not defined. Due to the limited availability of evidence, it is necessary to conduct methodologically quality controlled studies.
The gel has no odor, does not leave greasy stains.